Insys Therapeutics, Inc.
Insys Therapeutics, Inc. (INSY): 4 pipeline candidates · ~16 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
15.9 months
D/E -2.05 · 0% dilution
Lead: Approved
4 candidates
N/A
N/A
A transparent, data-derived signal for Insys Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$36.5M
Quarterly Burn
$16.7M
Runway
15.9 mo
Revenue
$7.6M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
| Drug | Phase |
|---|---|
| buprenorphine sublingual spray | Phase 3 |
| naloxone | Preclinical |
| subsys | Approved |
| syndros | Approved |
Frequently asked questions
How many drug candidates are in Insys Therapeutics, Inc.'s pipeline?
Insys Therapeutics, Inc. (INSY) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Insys Therapeutics, Inc.'s lead drug candidate?
Insys Therapeutics, Inc.'s most advanced tracked candidate is buprenorphine sublingual spray (Phase 3) for Acute pain.
What is Insys Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Insys Therapeutics, Inc. has approximately 15.9 months of cash runway.
Get the full picture on Insys Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.